Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness

WASHINGTON, May 25, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. today announced the results from its Phase III study of tradipitant in motion sickness, confirming the previously reported... | May 25, 2023

Related Keywords

Egypt ,Washington ,United States ,Spain ,Syros ,Perifereia Notiou Aigaiou ,Greece ,Spanish ,Greek ,Egyptian ,Eli Lilly ,Kevin Moran ,Us Department Of Transportation ,Vanda Pharmaceuticals Inc ,Twitter ,Bureau Of Transportation Statistics ,Exchange Commission ,Prnewswire Vanda Pharmaceuticals Inc ,Head Of Corporate Affairs ,Journal Of The Royal Society Medicine ,Motion Syros ,Spanish Armada ,Royal Society ,Statistics Annual ,Note Regarding Forward Looking ,Financial Condition ,Annual Report ,Quarterly Reports ,Current Reports ,Vice President ,Chief Financial Officer ,Vanda Pharmaceuticals Inc Stock Exchange ,News ,Information ,Press Release ,Bay ,023 ,Panda ,Pharmaceuticals ,Oday ,Nnounced ,The ,Results ,Rom ,Its ,Hase ,Wii ,Study ,F ,Radipitant ,N ,Lotion ,Aconfirming ,Reviously Vnda Us9216591084 ,